Results 221 to 230 of about 1,191,896 (339)
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Fully bio-based composite and modular metastructures. [PDF]
da Silva RJ +6 more
europepmc +2 more sources
High-Performance Phthalonitrile Resins Partially Derived from a Furan Bio-Based Chemical Platform. [PDF]
Poliakova DI +5 more
europepmc +1 more source
An Out‐of‐Place Etiology: Recognizing FMR1 Premutation in the Memory Clinic
ABSTRACT The FMR1 gene premutation (55–200 CGG repeats) is usually associated with a wide range of symptoms and phenotypes within the Fragile X‐tremor/ataxia syndrome (FXTAS), but may also manifest as predominant or isolated cognitive decline. We describe three male patients referred for progressive cognitive impairment and behavioral changes. Standard
Guido Greco +7 more
wiley +1 more source
An Overview of Bio-Based Polymers with Potential for Food Packaging Applications. [PDF]
Şomoghi R, Mihai S, Oancea F.
europepmc +1 more source
Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9
ABSTRACT Background Limb girdle muscular dystrophy type R9 (LGMDR9) results from biallelic variants in FKRP. There is limited data to predict loss of ambulation (LOA) among those with LGMDR9. Methods Participants in an ongoing dystroglycanopathy natural history study (NCT00313677) with FKRP variants who had achieved ambulation and were more than 3 ...
Chandra L. Miller +6 more
wiley +1 more source
Biodegradable PVA-Alginate Bio-Based Polymers Incorporating Cardanol-Based Polyols for Antibacterial Applications. [PDF]
Lee DH, Ahn HJ, Lee J, Woo HC.
europepmc +1 more source

